Novartis and Japanese firm Eisai's US subsidiary to co-promote Lenvima capsules in combination with everolimus to treat RCC

Switzerland's Novartis Pharmaceuticals has entered into an agreement with Eisai's US subsidiary to co-promote Lenvima (lenvatinib) capsules in combination with everolimus

, to treat patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy.

Everolimus is sold by Novartis in the US market as Afinitor tablets.

On 13 May, Lenvima was granted Breakthrough Therapy designation by the US FDA in combination with everolimus for this indication.

RCC is a kidney cancer usually found in adults and accounts for 90% of malignant kidney tumours.

Two main molecular pathways that are involved in the progression of advanced RCC include the mammalian target of rapamycin (mTOR) pathway and the vascular endothelial growth factor (VEGF) pathway.

The major goal of treating RCC is to block the growth of this malignant kidney tumour in the patient for as long as possible.

Lenvima targets the VEGF pathway, while everolimus targets the mTOR pathway.

Novartis oncology president Bruno Strigini said: "The goal of this collaboration is to inform physicians that they have a new step forward treatment option, which simultaneously blocks two key pathways in advanced renal cell carcinoma.

"Novartis has long experience in RCC, coupled with Japanese firm Eisai's equal commitment to cancer patients offers a combination of expertise we believe will be a positive force for the RCC community."

Under the deal, the two companies will, in collaboration, promote the availability of this combination regimen to appropriate healthcare professionals across the country.

Novartis and Eisai will also participate in some joint medical affairs activities in order to enable appropriate medical use of and medical education regarding the combination.

Reference: http://www.pharmaceutical-technology.com/news/newsnovartis-eisai-promote-lenvima-combination-everolimus-treat-rcc-4913713